Ann: Mayne Pharma provides update on 1Q FY24 trading and outlook, page-13

First 13 Last

Share
Profile

Follow
SHAREHOLDER33

967 Posts.

73

18/10/23

11:18

Post #: 70402167
Share

Originally posted by Dickkyboy: ↑

SH333: 92 mil total revenue in one quarter in 3 month multiply *4 =total group revnue 360 m versus 180 PY
plus adding Rhofade extra 20 m minus the seasonal liabilties minus cost reduction

Reality: With all the positive bits in that updates; the company still burnt $$$cash. Read- throw $100usd bills on the fire and watch what happens too them. Revenue doesn't matter if the company is throwing $100us bills on the fire. Everyone would prefer the $180m revenue with $120m expenses.

Revenue also doesn't matter when it is reducing in products you have paid huge $ for. This is why the market reacted negatively to 2H23 & TxMD. Also why you have the TxMD comments in this thread. This revenue isn't free - it was paid for. You seem to completely neglect that.

Revenue Growth won't drive share price growth (or the explosion we are waiting for) without controlling expenses, getting + EBITDA and generating a Net Profit. Too many investors have been burnt and this company has burnt $billions! There are positive signs in the update that the Executive is listening to investors (outlined in my other post).

That said;
revenue needs to grow in Nexstellis as we are paying a huge price by carrying it - this is why the company keeps talking about getting that runrate to breakeven - it's the starting point for earning back the $235m (expenses) expected at 1/2Y
revenue for TxMD neeeds to be growing- these are supposed to be good products and the 1/2H was disappointing.

Expand

check the seasonal expenses like warehouse expansion after adding back the seasonal expenses cost and the addition of the cost savings and adding rhofade revenue . it will return +ve EBITDA .Plus compared to PY less interest charged on the huge debt that was paid off and so improved EBITDA AS WELL SP will bounce back at least to $6.00 closer to half year update and don't forget the extra %5 buy back

MYX Price at posting: $3.15 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

What's causing the cost-of-living crisis, and how to navigate it

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins